Cellscape Corporation

VivaLNK, Inc is a leading provider of medical wearables and remote patient monitoring solutions based in Campbell, CA. Their innovative range of wearable devices includes ECG monitors, temperature monitors, SpO2 monitors, and BP cuffs, among others, enabling continuous and accurate data capture from patients in various healthcare settings. With a focus on biometrics data platform and software development, VivaLNK's RPM platform simplifies real-world data capture and offers multi-site consolidated data access for integration and analysis. Their solutions cater to a wide range of medical specialties, including cardiology, oncology, neurology, and respiratory care, empowering healthcare professionals to monitor patients remotely and conduct decentralized clinical trials with ease.Generated from the website

List Biological Laboratories, located in Campbell, California, specializes in the development and production of biotherapeutics, including bacterial toxins, polysaccharides, and recombinant proteins. The company offers a range of services, such as clinical facility operations, process development, and analytical testing, catering to diverse needs in the pharmaceutical and biotechnology sectors. With a commitment to innovation, List Labs provides custom services and products, including GMP-grade materials and various adjuvants and antibodies. Their expertise extends to the creation of live biotherapeutics and tailored solutions for clients seeking to advance their research and development projects. Generated from the website

Denali Therapeutics is a biotechnology company based in South San Francisco, CA, dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development. With a focus on Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative diseases, Denali utilizes groundbreaking scientific insights and deep expertise in genetics and pathology to develop effective molecular therapeutics. Driven by a commitment to partnering with patients, Denali's core portfolio consists of programs at various stages of clinical and preclinical development, aiming to directly address the causes and risk factors of neurodegenerative diseases. With a team of passionate scientists and drug developers, Denali believes in the power of collaboration and is continuously seeking new assets, technologies, and scientific insights to advance their mission of defeating degeneration.Generated from the website